[ad_1]
According to Interfax News, the ‘Russian Direct Investment Fund’ (RDIF), which is in charge of supporting the development of the Sputnik V vaccine and producing and supplying it abroad, tweeted: “If you use the Sputnik V vaccine for the second dose Vaccine AZ (AZ), “There is no need to wait three months for vaccination,” he said. “A clinical trial of this method (combined vaccination method) has already started.
The ‘Sputnik V’ vaccine stored in the warehouse of the Moscow cargo terminal▶ Click here to enlarge
He did not comment on specific details such as the location of the combined vaccination trial.
RDIF said earlier this month that Azerbaijan, the former Soviet Union, had approved a clinical trial for a combination of Sputnik V and AstraZeneca vaccines earlier this month.
Clinical trials are known to take place in the United Arab Emirates (UAE) and Saudi Arabia after Azerbaijan.
In November last year, Russia proposed a conjugate vaccination trial for AstraZeneca, and a consensus was reached after AZ accepted the proposal.
Both Sputnik V and AZ vaccines are carrier (vector) vaccines made by inserting the Corona 19 virus gene into another virus (carrier) that is harmless to the human body.
Sputnik V uses adenovirus types 5 and 26, which are common cold viruses, as vectors for two inoculations.
On the other hand, the Corona 19 vaccine developed by AstraZeneca with the University of Oxford in the UK is based solely on adenovirus type 5.
The combined Sputnik V and AstraZeneca vaccination trial is reported to be carried out for 6 months with 100 volunteers each in three countries, including Azerbaijan.
It is known that both sides are injecting the first dose with the AZ vaccine using adenovirus type 5 as a vector, and after a certain period of time, it is known that a second injection of the adenovirus type 26 Sputnik V vaccine is done.
Russia and the United Kingdom hope to increase the immunological effect of the vaccine through a combined vaccination of each vaccine.
Meanwhile, RDIF CEO Kirill Dmitryev said in an interview with Austrian radio station ’01’ that negotiations for the production of the Sputnik V vaccine in Austria are currently underway with various local companies.
“Austria has some of the best pharmaceutical companies in the world,” he said. “We want to establish a partnership between Austria and the Sputnik V vaccine for local production and export.”
RDIF has so far signed contracts for the production of local shipments with China, India, Iran and Korea.
“We are sending support for the Sputnik V vaccine from Austria, Germany, France and Italy,” Dmitryev said. “These national leaders say that the population should have the opportunity to choose a vaccine.”
“Everyone is trying to find some political element in the vaccine, but none,” he said, dismissing Western criticism that Russia is using the Sputnik V vaccine as a means to expand its political influence.
[연합뉴스]
Copyright ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited
